Tiotropium + olodaterol shows clinically meaningful improvements in quality of life
Dave Singh(University of Manchester), Leif Bjermer(Lund University), R Abrahams(Pulmonary Associates), Nathan Bennett(Boehringer Ingelheim (United States)), Gary T. Ferguson(Pulmonary Associates), Christoph Hallmann(Boehringer Ingelheim (Germany)), J Bolitschek(Krankenhaus der Elisabethinen), Olaf Schmidt, Lars Grönke(Boehringer Ingelheim (Germany))
Cited by 174
Related Papers
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329